62 17. SAFETY, TOXICITY, AND ADVERSE EVENTS ..............................................63 17.1 Toxicity associated with Standard Therapy (HDC + PBSCT) .................... 63 17.2 Immunotherapy Related Dose- limiting Toxicity .........................................